{"product_id":"xerispharma-five-forces-analysis","title":"Xeris Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cpxeris faces nuanced competitive pressures supplier bargaining to emerging substitutes shape its pricing power and growth trajectory this snapshot highlights key tension points strategic levers.\u003e\n\u003c\/pxeris\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API Manufacturing Reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris depends on a small set of specialized API suppliers for Gvoke and Recorlev; in 2024 over 70% of API volume traced to two vendors, raising switching costs due to regulatory validation and proprietary specs.\u003c\/p\u003e\n\u003cp\u003eThese suppliers command pricing power—API cost spikes of 15–25% in 2023–24 for comparable molecules show exposure—and can delay supplies, risking revenue hits given Xeris’s limited inventory buffers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of high-purity non-aqueous solvents and specialized delivery components exert strong leverage over Xeris because XeriSol and XeriJect formulations are tuned to those inputs; about 70% of active manufacturing cost for similar depot injectables stems from specialty chemicals (2024 industry data).\u003c\/p\u003e\n\u003cp\u003eAny single-source disruption could push time-to-market beyond the planned 2026 commercialization, raising COGS by an estimated 15–30% and forcing Xeris to pay 20–40% premium for alternate suppliers or invest in in-house synthesis capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Compliance Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers in biopharma face strict FDA and EMA rules, which in 2024 left fewer than 200 global CGMP (current Good Manufacturing Practice) vendors for parenterals, narrowing Xeris’s vendor pool.\u003c\/p\u003e\n\u003cp\u003eXeris’s approved filings tie it to specific suppliers; swapping a primary vendor triggers months-long re-validation and can delay product launches by 6–12 months per industry averages.\u003c\/p\u003e\n\u003cp\u003eThat regulatory lock-in raises supplier bargaining power, letting vendors push for higher prices or stricter terms—industry surveys show 15–25% premium for qualified, compliant suppliers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale and Volume Limitations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a mid-sized biopharma, Xeris lacks the purchasing scale of top pharma firms (Pfizer 2024 buy volumes \u0026gt;$40B), so it cannot secure comparable volume discounts and faces higher per-unit costs.\u003c\/p\u003e\n\u003cp\u003eSuppliers often prioritize larger clients during shortages—COVID-era API shortages saw top buyers get 60–80% of supply; smaller firms like Xeris took proportionally less—forcing Xeris to accept tighter lead times and worse payment terms to keep production steady.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmaller purchase volumes → higher unit costs\u003c\/li\u003e\n\u003cli\u003eSuppliers favor big clients in shortages (60–80% allocation)\u003c\/li\u003e\n\u003cli\u003eResult: accept worse pricing, lead times, payment terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property of Sub-components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf a supplier holds patents on auto-injector sub-components, Xeris faces high barriers to vertical integration and must pay premium licensing or long-term contract prices; in 2024 medical-device patent disputes increased supplier leverage by ~18% in deal value adjustments.\u003c\/p\u003e\n\u003cp\u003eTechnical dependency raises supplier bargaining power, risking supply interruptions and margin pressure for Xeris given limited alternative manufacturers and specialized tooling lead times of 9–14 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatented component = high switching cost\u003c\/li\u003e\n\u003cli\u003eLicensing raises COGS and fixed costs\u003c\/li\u003e\n\u003cli\u003eLong lead times enable supplier leverage\u003c\/li\u003e\n\u003cli\u003eLimited alternatives concentrate risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Concentration Risks: Top-2 APIs \u0026gt;70%, shortages could spike COGS 15–30%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: two API vendors supplied \u0026gt;70% of Xeris volume in 2024, API costs rose 15–25% in 2023–24, single-source disruptions could raise COGS 15–30% and force 20–40% premium sourcing; CGMP parenteral vendors numbered \u0026lt;200 globally (2024), and revalidation swaps take 6–12 months, favoring large buyers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-2 API share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI price spike\u003c\/td\u003e\n\u003ctd\u003e15–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCGMP parenteral vendors\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevalidation delay\u003c\/td\u003e\n\u003ctd\u003e6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential COGS rise (disruption)\u003c\/td\u003e\n\u003ctd\u003e15–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces assessment for Xeris, highlighting competitive intensity, supplier and buyer power, threat of substitutes, and barriers to entry with strategic implications for pricing and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-sheet for Xeris—quickly spot relief points like weakened supplier power or softened buyer bargaining to guide immediate strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of PBMs and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBMs and insurers, which control formulary placement, are Xeris Therapeutics major customers; the top 3 PBMs covered roughly 80% of US lives in 2024, concentrating buying power. These payers can demand rebates often exceeding 30% of list price to secure preferred tiers, cutting net revenue per unit. If Gvoke misses preferred status, patient access drops and script volumes can fall by 50%+ within a year, shrinking sales rapidly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Distributor Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Xeris Therapeutics’ 2024 product revenue—about 62% of net sales—comes from sales to a handful of major wholesalers, giving those distributors strong bargaining power over credit terms and distribution fees. These wholesalers control logistics into ~40,000 U.S. pharmacies and hospital channels, so they can delay payments or demand higher fees that squeeze Xeris’ margins. Xeris depends on these partners to keep Gvoke and other products on shelf and in hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity of Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppublic and private payers increasingly demand cost-containment value-based care cms programs link of medicare payments to quality or cost metrics so xeris must prove roi. decision-makers assess glucagon alternatives on like avoided er visits each preventing even a small number justifies higher unit price. if premium exceeds measured savings versus generics hospitals will pressure for discounts formulary exclusion hospital negotiations cut launch prices by average.\u003e\n\u003c\/ppublic\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician Prescribing Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePhysicians, not patients, control access to Xeris products through prescribing; in 2024 about 78% of endocrine prescriptions were clinician-initiated decisions tied to efficacy and ease of use.\u003c\/p\u003e\n\u003cp\u003eDoctors weigh clinical outcomes, device simplicity, and payor coverage—formularies drove a 22% volume shift to preferred branded injectables in 2023, so insurance status matters.\u003c\/p\u003e\n\u003cp\u003eIf competitors match efficacy but offer better patient support or lower net cost, Xeris risks share loss; rival patient-support programs cut churn by ~15% in recent studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysicians = gatekeepers; 78% clinician-driven prescriptions (2024)\u003c\/li\u003e\n\u003cli\u003eFormulary placement caused 22% volume shifts (2023)\u003c\/li\u003e\n\u003cli\u003ePatient-support lowers churn ~15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups in endocrinology can sway payer formularies; campaigns raised insulin access to US Congress in 2023, pushing price concessions and affecting coverage decisions.\u003c\/p\u003e\n\u003cp\u003eXeris should spend heavily on patient education to drive demand for ready-to-use glucagon; a 2024 survey found 42% of patients choose treatments they understand well.\u003c\/p\u003e\n\u003cp\u003eHigh out-of-pocket costs raise buyer power—46% of US patients skipped prescriptions for cost in 2022—so price sensitivity can push users to cheaper injectables.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy influences payer priorities and formulary placement\u003c\/li\u003e\n\u003cli\u003eEducation boosts patient pull-through; 42% choose familiar options\u003c\/li\u003e\n\u003cli\u003e46% skipped meds for cost in 2022 → higher buyer power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePowerful PBMs, steep rebates \u0026amp; patient price pain reshape drug access and pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePBMs\/insurers and a few wholesalers hold concentrated buying power—top 3 PBMs cover ~80% of US lives (2024); rebates often exceed 30%, and loss of preferred status can cut scripts \u0026gt;50% within a year. Payers tie ~40% Medicare payments to value (2024); ER hypoglycemia costs $3k–$5k, so proven cost-savings justify price. Physicians drive ~78% prescriptions (2024); patient price sensitivity high—46% skipped meds (2022).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 PBM coverage (2024)\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical rebate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare value-linkage (2024)\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician-driven scripts (2024)\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients skipping meds (2022)\u003c\/td\u003e\n\u003ctd\u003e46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eXeris Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Xeris Porter’s Five Forces analysis you’ll receive after purchase—fully formatted, professionally written, and ready to download immediately.\u003c\/p\u003e\n\u003cp\u003eNo mockups or samples: the document displayed is the final deliverable, identical to the file you’ll get upon payment, with comprehensive evaluation of competitive rivalry, supplier and buyer power, threats of substitution and entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747115184505,"sku":"xerispharma-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/xerispharma-five-forces-analysis.png?v=1772195036","url":"https:\/\/matrixbcg.com\/products\/xerispharma-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}